Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas strengthens its US Commercial Organization

Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN

The pivotal Phase 3 clinical trial NefIgArd Part A fully recruited

Calliditas Therapeutics Capital Markets Day today November 4

Save the date: Calliditas to host Capital Markets Day in Stockholm on November 4, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report

Calliditas Therapeutics to Present at Redeye Growth Day

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report

Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics

Calliditas Therapeutics to Present at the Needham Healthcare Conference

Calliditas Therapeutics to Present at March Investor Conferences

Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report

Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America

Calliditas Therapeutics to present and attend investor conferences in November 2018

Calliditas Therapeutics to host conference call to provide Q3 2018 Business Update

Presentation at International IgA Nephropathy Network meeting highlighting supportive post-hoc analysis of the NEFIGAN study

Post-hoc results from NEFIGAN study to be presented at the International IgA Nephropathy Network meeting (IIgANN)

Calliditas Therapeutics to host conference call to provide Q2 2018 Business Update

The 15th International Symposium on IgA nephropathy accepts Calliditas Therapeutics abstracts

Calliditas Therapeutics selected to present at the 25th Annual NewsMakers in the Biotech Industry

Trading in Calliditas’ share commences today on Nasdaq Stockholm

Pharmalink enters manufacturing agreement for Nefecon®